PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease

BACKGROUND: We previously demonstrated that subcutaneous administration of PT320, a sustained-release (SR) form of exendin-4, resulted in the long-term maintenance of steady-state exenatide (exendin-4) plasma and target levels in 6-hydroxydopamine (6-OHDA)-pretreated animals. Additionally, pre- or p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Seong-Jin, Chen, Shuchun, Yang, Yung-Yung, Glotfelty, Elliot J., Jung, Jin, Kim, Hee Kyung, Choi, Ho-Il, Choi, Doo-Sup, Hoffer, Barry J., Greig, Nigel H., Wang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431885/
https://www.ncbi.nlm.nih.gov/pubmed/32848559
http://dx.doi.org/10.3389/fnins.2020.00785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431885/
https://www.ncbi.nlm.nih.gov/pubmed/32848559
http://dx.doi.org/10.3389/fnins.2020.00785

Ejemplares similares